Figure 2

NALP1 mRNA expression in 31 human colorectal cancer tissues. (a) The human colorectal cancer tissue qRT-PCR array was used to measure transcript levels of NALP1 mRNA. For the human tissue array, tissues were selected from 33 individuals with cancer of different stages, except patients 1 and 6. The sample information is described in Table 1. The y axis represents the relative transcript value of NALP1 mRNA. Data were obtained using the comparative C_T method, and the data were normalized to GAPDH levels and the matched-pairs normal colorectal tissue. The bar with the sign (^★) indicates a relative transcript value >1. (b) The transcript levels of NALP1 in human colorectal normal and cancer tissue, respectively. The qRT-PCR array was used to measure the transcript levels of NALP1 mRNA. The y axis represents the mean±S.D. for human colorectal normal and cancer tissues as individual data points using 2^-ΔCt [2^{-(Ct NALP1-CtGAPDH)}]. The S.D. was calculated from these data. The mean±S.D. 2^-ΔCt for the normal and cancerous tissues was 0.616±1.642 and 0.066±0.152, respectively, and the difference was highly statistically significant as determined by Wilcoxon signed-rank nonparametric test; the P-values are represented by asterisks (**P<0.01). (c) The fold induction in NALP1 mRNA expression in the human colorectal normal group compared with the human colorectal cancer group. The fold induction is 0.616/0.066- or 9.34-fold. Details are provided in the ‘Materials and Methods’ section. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; qRT-PCR, quantitative real-time PCR